Clinical Trial Update: A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for NOV-205 in hepatitis C patients who failed standard therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• NOV-205

Snippet

Sponsor: Cellectar Biosciences, Inc. | Conditions: Hepatitis C | Phase 2 | Status: COMPLETED